Christina Jewett / nytimes - The agency’s top food official will step in as acting commissioner, after Dr. Makary’s tumultuous run as the nation’s top food, drug, tobacco and medical device regulator.
AI Summary: F.D.A. commissioner Marty Makary resigned after weeks of intense scrutiny and internal pressure over leadership and policy choices, following reports he faced possible removal. The agency now confronts leadership turbulence as officials rush to steady regulatory priorities, reassure stakeholders and clean up an exit that leaves unfinished reviews and awkward staff memos.
FDA Abortion Pill Decisions Rooted in Science / 4 months
FDA loosens data restrictions to accelerate drug reviews / 5 months
FDA Appoints Richard Pazdur to Lead Drug Division Amid Regulatory Shifts / 6 months
FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 1 month
FDA approves leucovorin for rare folate disorder despite autism hype / 2 months
FDA launches individualized therapy framework for ultra-rare diseases / 3 months
FDA makes one pivotal trial the default for drug approvals / 3 months
StackHealth RSS

StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.